Amicus Therapeutics Completes Merger with BioMarin, Becomes Wholly-Owned Subsidiary
FOLD has more than doubled off its 52-week low of $5.51.
Summary
Amicus Therapeutics has completed its merger with BioMarin Pharmaceutical Inc., becoming a wholly-owned subsidiary and terminating all outstanding securities registrations.
Key Events · M&A and Partnerships · FOLD
-
Merger Finalized
Amicus Therapeutics, Inc. has officially completed its merger with BioMarin Pharmaceutical Inc. on April 27, 2026.
-
Becomes Wholly-Owned Subsidiary
As a result of the merger, Amicus Therapeutics is now a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
-
Securities Deregistration
All previously registered securities offerings by Amicus have been terminated, and unsold securities are being removed from registration.
-
Cessation of Independent Trading
This event marks the end of Amicus Therapeutics as an independent publicly traded company.
Analysis · FOLD · Life Sciences
This filing officially confirms the completion of the merger between Amicus Therapeutics and BioMarin Pharmaceutical Inc., following the French regulatory clearance announced just days prior. As a result, Amicus Therapeutics is now a wholly-owned subsidiary of BioMarin, marking the end of its independent public trading status. All previously registered securities offerings by Amicus have been terminated, and unsold securities are being deregistered. This event finalizes the acquisition process, which saw Amicus's stock trading near its 52-week high, reflecting the market's anticipation and pricing of the deal.
At the time of this filing, FOLD was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.50. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.